Simone Salemme
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simone Salemme has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Manuela Tondelli
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
7 shared publications Annalisa Chiari
6 shared publications- Giovanna Zamboni
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
6 shared publications Giovanna Zamboni
Neurology Unit, Azienda Ospedaliero-Universitaria Di Modena, Modena, Italy
5 shared publications- Chiara Carbone
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy
4 shared publications Giulia Vinceti
Neurology Unit, Baggiovara Hospital, AOU Modena, Modena, Italy
4 shared publications
Latest Publications
- 8 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (5)
Menopausal Hormone Therapy and Alzheimer Disease
- 8 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (5)
Menopausal Hormone Therapy and Alzheimer Disease
- 8 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (5)
Blood-Based Biomarkers for Alzheimer Disease in Primary Care
- 8 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (5)
Blood-Based Biomarkers for Alzheimer Disease in Primary Care
- Open Access
- 13 August 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (9)
From regulatory approval to clinical practice: real-world eligibility for anti-amyloid monoclonal antibodies in an Italian dementia-care network
- 13 August 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (9)
Open AccessFrom regulatory approval to clinical practice: real-world eligibility for anti-amyloid monoclonal antibodies in an Italian dementia-care network
- Open Access
- 28 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1005059
The principles of Population-Level Approaches to Dementia Risk Reduction (PLADRR)
Author summary Dementia is a leading health policy challenge, with cases expected to triple by 2050, particularly in low- and middle-income countries. Epidemiological evidence demonstrates falling age-specific incidence rates in high-income countries, suggesting risk can be lowered at the population level. The Population-Level Approaches to Dementia Risk Reduction (PLADRR) Research Group is a diverse, international network of researchers committed to investigating how structural, social, and environmental conditions can promote life course brain health and reduce dementia risk across the population. This Policy Forum article sets out the guiding principles of our approach, the building blocks required, our research priorities, and how PLADRR research can inform and translate into policy changes.
- 28 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1005059
Open AccessThe principles of Population-Level Approaches to Dementia Risk Reduction (PLADRR)
Author summary Dementia is a leading health policy challenge, with cases expected to triple by 2050, particularly in low- and middle-income countries. Epidemiological evidence demonstrates falling age-specific incidence rates in high-income countries, suggesting risk can be lowered at the population level. The Population-Level Approaches to Dementia Risk Reduction (PLADRR) Research Group is a diverse, international network of researchers committed to investigating how structural, social, and environmental conditions can promote life course brain health and reduce dementia risk across the population. This Policy Forum article sets out the guiding principles of our approach, the building blocks required, our research priorities, and how PLADRR research can inform and translate into policy changes.
- Open Access
Recommendations for structural magnetic resonance imaging in infants with first afebrile seizure or new onset epilepsy: Evidence‐based recommendations from the ILAE Neuroimaging Task Force
Infants aged 1–24 months with new onset epilepsy frequently present with structural brain abnormalities, yet no updated evidence‐based magnetic resonance imaging (MRI) guidelines exist for this population. The International League Against Epilepsy (ILAE) Neuroimaging Task Force developed evidence‐based recommendations for structural brain MRI in infants with a first afebrile seizure or new onset epilepsy. A multidisciplinary panel defined three PICO (patients, intervention, comparison group, outcome under consideration) questions, conducted a systematic review (PROSPERO [Prospective Register of Systematic Reviews] CRD42024592653), and reported the results in line with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) 2020 guidelines. Risk of bias was evaluated using the JBI (Joanna Briggs Institute) checklist. GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology was used to assess certainty of evidence and formulate recommendations for the following: (1) the effectiveness of MRI in identifying underlying etiologies, (2) clinical predictors of MRI abnormalities, and (3) MRI protocols. Seventeen studies ( n = 1209) were included. Among 753 infants who underwent MRI, 438 (58.2%) had abnormal findings. Despite heterogeneity in MRI protocols and reporting, the evidence supports the utility of MRI in this population. Specific clinical features (focal seizure semiology, abnormal neurological examination, seizure duration > 5 min, focal electroencephalographic abnormalities, developmental delay, and perinatal complications) were associated with abnormal MRI findings, although methodological limitations reduce certainty. Only six studies provided data on MRI sequences; however, none reported findings specifically in relation to the diagnostic accuracy or yield of individual protocols, precluding the development of evidence‐based recommendations on MRI protocol selection. MRI is conditionally recommended in all infants with a first afebrile seizure or new onset epilepsy. MRI could be prioritized in those with specific clinical features indicative of higher likelihood of abnormal findings. Recommendations are based on very low certainty of evidence. These are the first ILAE‐endorsed, evidence‐based recommendations for MRI in infants with first afebrile seizure or new onset epilepsy. Further prospective studies with standardized protocols are needed to refine MRI indications and optimize diagnostic yield in this age group.
Open AccessRecommendations for structural magnetic resonance imaging in infants with first afebrile seizure or new onset epilepsy: Evidence‐based recommendations from the ILAE Neuroimaging Task Force
Infants aged 1–24 months with new onset epilepsy frequently present with structural brain abnormalities, yet no updated evidence‐based magnetic resonance imaging (MRI) guidelines exist for this population. The International League Against Epilepsy (ILAE) Neuroimaging Task Force developed evidence‐based recommendations for structural brain MRI in infants with a first afebrile seizure or new onset epilepsy. A multidisciplinary panel defined three PICO (patients, intervention, comparison group, outcome under consideration) questions, conducted a systematic review (PROSPERO [Prospective Register of Systematic Reviews] CRD42024592653), and reported the results in line with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) 2020 guidelines. Risk of bias was evaluated using the JBI (Joanna Briggs Institute) checklist. GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology was used to assess certainty of evidence and formulate recommendations for the following: (1) the effectiveness of MRI in identifying underlying etiologies, (2) clinical predictors of MRI abnormalities, and (3) MRI protocols. Seventeen studies ( n = 1209) were included. Among 753 infants who underwent MRI, 438 (58.2%) had abnormal findings. Despite heterogeneity in MRI protocols and reporting, the evidence supports the utility of MRI in this population. Specific clinical features (focal seizure semiology, abnormal neurological examination, seizure duration > 5 min, focal electroencephalographic abnormalities, developmental delay, and perinatal complications) were associated with abnormal MRI findings, although methodological limitations reduce certainty. Only six studies provided data on MRI sequences; however, none reported findings specifically in relation to the diagnostic accuracy or yield of individual protocols, precluding the development of evidence‐based recommendations on MRI protocol selection. MRI is conditionally recommended in all infants with a first afebrile seizure or new onset epilepsy. MRI could be prioritized in those with specific clinical features indicative of higher likelihood of abnormal findings. Recommendations are based on very low certainty of evidence. These are the first ILAE‐endorsed, evidence‐based recommendations for MRI in infants with first afebrile seizure or new onset epilepsy. Further prospective studies with standardized protocols are needed to refine MRI indications and optimize diagnostic yield in this age group.
- Open Access
- 24 March 2026
- Published by Elsevier in The Lancet Public Health
- Vol. 11 (5) , e277-e278
Operationalising dementia prevention as a measurable NCD priority
- 24 March 2026
- Published by Elsevier in The Lancet Public Health
- Vol. 11 (5) , e277-e278
Open AccessOperationalising dementia prevention as a measurable NCD priority
- 13 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (4) , 1404-1405
Deciphering the A–T+ enigma: Clinical relevance or diagnostic noise?
A recent Danish memory clinic cohort study sheds light on the enigmatic A–T+ biomarker profile – defined by elevated CSF p-tau181 in the absence of amyloid pathology. This commentary explores the clinical and conceptual implications of A–T+, arguing that it reflects a heterogeneous, non-Alzheimer group and highlighting the need to rethink A–T+ within a broader neurobiological framework. A–T+ is not diagnostic noise, but a call to investigate diverse pathways of neurodegeneration beyond amyloid-tau paradigms.
- 13 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (4) , 1404-1405
Deciphering the A–T+ enigma: Clinical relevance or diagnostic noise?
A recent Danish memory clinic cohort study sheds light on the enigmatic A–T+ biomarker profile – defined by elevated CSF p-tau181 in the absence of amyloid pathology. This commentary explores the clinical and conceptual implications of A–T+, arguing that it reflects a heterogeneous, non-Alzheimer group and highlighting the need to rethink A–T+ within a broader neurobiological framework. A–T+ is not diagnostic noise, but a call to investigate diverse pathways of neurodegeneration beyond amyloid-tau paradigms.
- Open Access
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002250
Advancing dementia care: a review of Italy’s public health response within the WHO Global Action Plan and European strategies
Introduction: Dementia is a growing global public health priority, with the WHO Global Action Plan (GAP) calling for coordinated efforts worldwide. Italy, one of the oldest nations globally, faces a significant challenge with approximately 2 million individuals living with dementia or mild cognitive impairment. In response, the Italian Fund for Alzheimer’s and other Dementias (IFAD) was established in 2020 to align national efforts with the WHO GAP’s objectives. This study analyses IFAD activities from 2021 to 2023, offering insights into Italy’s public health response to dementia and its relevance to global strategies. Methods: We conducted a structured, iterative review of all activities coordinated by the Italian Dementia Observatory (OssDem-Istituto Superiore di Sanità (ISS)) within IFAD 2021–2023. Global, regional and national documents on dementia prevention, care and support were retrieved from official websites, institutional repositories and targeted web searches using the keywords ‘dementia’, ‘brain health’ and ‘ageing’. Two reviewers independently screened and extracted data with a predefined matrix mapped to the seven WHO GAP Action Areas. Human-subject studies cited had independent ethics approval and informed consent; no new data were collected for this review. Results: IFAD activities led to substantial progress in dementia care services, with memory clinics, residential care facilities and daycare centres mapped, revealing regional disparities in service provision. Modifiable risk factors accounted for 39.5% of dementia cases in Italy, with an estimated 67 000 cases preventable through risk reduction. National guidelines were developed to standardise dementia care pathways, and training programmes addressed gaps in HP and caregiver preparedness, particularly highlighted by the COVID-19 pandemic. Discussion: Italy’s experience provides valuable lessons for countries facing similar demographic challenges. The IFAD extension to 2024–2026 aims to address persistent regional disparities and further implement national guidelines and prevention strategies. By integrating Italy’s progress with broader international frameworks, the Italian model can inform global efforts to enhance dementia care, highlighting the importance of scalable, regionally adapted strategies for addressing the growing global burden of dementia.
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002250
Open AccessAdvancing dementia care: a review of Italy’s public health response within the WHO Global Action Plan and European strategies
Introduction: Dementia is a growing global public health priority, with the WHO Global Action Plan (GAP) calling for coordinated efforts worldwide. Italy, one of the oldest nations globally, faces a significant challenge with approximately 2 million individuals living with dementia or mild cognitive impairment. In response, the Italian Fund for Alzheimer’s and other Dementias (IFAD) was established in 2020 to align national efforts with the WHO GAP’s objectives. This study analyses IFAD activities from 2021 to 2023, offering insights into Italy’s public health response to dementia and its relevance to global strategies. Methods: We conducted a structured, iterative review of all activities coordinated by the Italian Dementia Observatory (OssDem-Istituto Superiore di Sanità (ISS)) within IFAD 2021–2023. Global, regional and national documents on dementia prevention, care and support were retrieved from official websites, institutional repositories and targeted web searches using the keywords ‘dementia’, ‘brain health’ and ‘ageing’. Two reviewers independently screened and extracted data with a predefined matrix mapped to the seven WHO GAP Action Areas. Human-subject studies cited had independent ethics approval and informed consent; no new data were collected for this review. Results: IFAD activities led to substantial progress in dementia care services, with memory clinics, residential care facilities and daycare centres mapped, revealing regional disparities in service provision. Modifiable risk factors accounted for 39.5% of dementia cases in Italy, with an estimated 67 000 cases preventable through risk reduction. National guidelines were developed to standardise dementia care pathways, and training programmes addressed gaps in HP and caregiver preparedness, particularly highlighted by the COVID-19 pandemic. Discussion: Italy’s experience provides valuable lessons for countries facing similar demographic challenges. The IFAD extension to 2024–2026 aims to address persistent regional disparities and further implement national guidelines and prevention strategies. By integrating Italy’s progress with broader international frameworks, the Italian model can inform global efforts to enhance dementia care, highlighting the importance of scalable, regionally adapted strategies for addressing the growing global burden of dementia.
- Open Access
- 10 April 2025
- Published by Elsevier in Brain and Cognition
- Vol. 186, 106297
Cognitive reserve in young-onset cognitive impairment
- 10 April 2025
- Published by Elsevier in Brain and Cognition
- Vol. 186, 106297
Open AccessCognitive reserve in young-onset cognitive impairment
- Top Cited PapersOpen Access
- 1 January 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 17 (1) , e70074
The prognosis of mild cognitive impairment: A systematic review and meta‐analysis
INTRODUCTION: Knowledge gaps remain about the prognosis of mild cognitive impairment (MCI). Conversion rates to dementia vary widely, and reversion to normal cognition has gained attention. This review updates evidence on MCI conversion risk and probability of stability and reversion.METHODS: We searched databases for studies on MCI prognosis with ≥3 years of follow‐up, established criteria for MCI and dementia, and performed a meta‐analysis using a random‐effects model to assess conversion risk, reversion, and stability probability. Meta‐regressions identified sources of heterogeneity and guided subgroup analysis.RESULTS: From 89 studies (mean follow‐up: 5.2 years), conversion risk was 41.5% (38.3%–44.7%) in clinical and 27.0% (22.0%–32.0%) in population‐based studies, with Alzheimer's dementia as the most common outcome. Stability rates were 49.3% (clinical) and 49.8% (population). Reversion was 8.7% (clinical) and 28.2% (population).DISCUSSION: Our findings highlight higher conversion in clinical settings and 30% reversion in population studies, calling for sustainable care pathway development.Highlights: Prognosis for mild cognitive impairment (MCI) varies by setting; dementia risk is higher and the probability of reversion is lower in clinical‐based studies. In both clinical and population settings, cognitive stability is ≈50%. A reorganization of health services could ensure sustainable care for individuals with MCI. Significant heterogeneity in MCI studies impacts data interpretation; follow‐up length is crucial. Long‐term prognosis studies on MCI in low‐ and middle‐income countries are urgently needed.
- 1 January 2025
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 17 (1) , e70074
Top Cited PapersOpen AccessThe prognosis of mild cognitive impairment: A systematic review and meta‐analysis
INTRODUCTION: Knowledge gaps remain about the prognosis of mild cognitive impairment (MCI). Conversion rates to dementia vary widely, and reversion to normal cognition has gained attention. This review updates evidence on MCI conversion risk and probability of stability and reversion.METHODS: We searched databases for studies on MCI prognosis with ≥3 years of follow‐up, established criteria for MCI and dementia, and performed a meta‐analysis using a random‐effects model to assess conversion risk, reversion, and stability probability. Meta‐regressions identified sources of heterogeneity and guided subgroup analysis.RESULTS: From 89 studies (mean follow‐up: 5.2 years), conversion risk was 41.5% (38.3%–44.7%) in clinical and 27.0% (22.0%–32.0%) in population‐based studies, with Alzheimer's dementia as the most common outcome. Stability rates were 49.3% (clinical) and 49.8% (population). Reversion was 8.7% (clinical) and 28.2% (population).DISCUSSION: Our findings highlight higher conversion in clinical settings and 30% reversion in population studies, calling for sustainable care pathway development.Highlights: Prognosis for mild cognitive impairment (MCI) varies by setting; dementia risk is higher and the probability of reversion is lower in clinical‐based studies. In both clinical and population settings, cognitive stability is ≈50%. A reorganization of health services could ensure sustainable care for individuals with MCI. Significant heterogeneity in MCI studies impacts data interpretation; follow‐up length is crucial. Long‐term prognosis studies on MCI in low‐ and middle‐income countries are urgently needed.